INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

NCT05416307 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB

NCT05063110 ·Status: COMPLETED ·Phase: PHASE2

Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)

NCT02007239 ·Status: WITHDRAWN ·Phase: PHASE2

Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis

NCT04120090 ·Status: UNKNOWN ·Phase: PHASE3

Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

NCT01104025 ·Status: COMPLETED ·Phase: PHASE2

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

NCT00266565 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

NCT04551131 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Zanubrutinib for HLH

NCT05320575 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis

NCT03312751 ·Status: COMPLETED ·Phase: PHASE3

Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders

NCT00267501 ·Status: RECRUITING

Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis

NCT05491304 ·Status: RECRUITING ·Phase: PHASE4

A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients

NCT05744063 ·Status: COMPLETED ·Phase: PHASE4

Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients

NCT05084872 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Ruxolitinib Combined With Dexamethasone for HLH

NCT03795909 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Study of Mast Cell Precursors

NCT00001756 ·Status: COMPLETED

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

NCT01818492 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis

NCT06951971 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

NCT03985423 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

NCT06325709 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic

NCT00244686 ·Status: NO_LONGER_AVAILABLE

Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

NCT00097370 ·Status: TERMINATED ·Phase: PHASE3

Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome

NCT00017862 ·Status: COMPLETED ·Phase: PHASE2

Monitoring Chronic Urticaria Basophil Irritability by Cytometry

NCT02671006 ·Status: COMPLETED

Safety and Efficacy of Gene Therapy of FHL Type 3 Caused by Mutations in the Human UNC13D Gene by Transplantation of a Single Dose of Autologous CD34+ Cells Transduced ex Vivo With the UNC13D LV Vector Expressing the UNC13D cDNA

NCT06736080 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Patient-Reported Outcome Questionnaire for Systemic Mastocytosis

NCT02380222 ·Status: COMPLETED